

## Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

March 3, 2026 at 8:30 AM EST

CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.<sup>®</sup> (the "Company") (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the Leerink Partners Global Healthcare Conference in Miami, FL on Tuesday, March 10, 2025 at 1:00 p.m. ET.

The webcast of the presentation will be accessible [HERE](#) or by visiting the "Events and Presentations" section of Fulcrum Therapeutics' website at <https://ir.fulcrumtx.com/events-and-presentations>. A replay of the webcast will be available on Fulcrum Therapeutics' website for at least 30 days following the presentation.

### **About Fulcrum Therapeutics**

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's lead clinical program is pociredir, a small molecule designed to increase expression of HbF for the treatment of SCD. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit [www.fulcrumtx.com](http://www.fulcrumtx.com) and follow us on X (@FulcrumTx) and LinkedIn.

### **Contact:**

Kevin Gardner  
LifeSci Advisors, LLC  
[kgardner@lifesciadvisors.com](mailto:kgardner@lifesciadvisors.com)  
617-283-2856